Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer

BACKGROUND: Cancer cachexia and tumor burden predict efficacies of programmed cell death‐1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors and chemotherapy or pembrolizumab in non‐small cell lung cancer (NSCLC). There are no predictive models that simultaneously assess cancer cachexia and tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyawaki, Taichi, Naito, Tateaki, Doshita, Kosei, Kodama, Hiroaki, Mori, Mikiko, Nishioka, Naoya, Iida, Yuko, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Takahashi, Kazuhisa, Takahashi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284192/
https://www.ncbi.nlm.nih.gov/pubmed/35698259
http://dx.doi.org/10.1111/1759-7714.14529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284192/
https://www.ncbi.nlm.nih.gov/pubmed/35698259
http://dx.doi.org/10.1111/1759-7714.14529

Ejemplares similares